Birgitta Versluijs

18 1 References 1. Matchis F. Europdonor Foundation An- nual Report 2015. 2. Mallhi K, Lum LG, Schultz KR, Yankele- vich M. Hematopoietic cell transplan- tation and cellular therapeutics in the treatment of childhood malignancies. Pediatric clinics of North America. 2015;62(1):257-73. 3. Chiesa R, Wynn RF, Veys P. Haemato- poietic stem cell transplantation in in- born errors of metabolism. Current opi- nion in hematology. 2016;23(6):530-5. 4. Peffault de Latour R, Peters C, Gibson B, Strahm B, Lankester A, de Heredia CD, et al. Recommendations on he- matopoietic stem cell transplantation for inherited bone marrow failure syn- dromes. Bone marrow transplantation. 2015;50(9):1168-72. 5. Robinson TM, Fuchs EJ. Allogeneic stem cell transplantation for sickle cell disease. Current opinion in hematology. 2016;23(6):524-9. 6. Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E. 2017 Clinical trials up- date in new treatments of beta-thalas- semia. American journal of hematology. 2016;91(11):1135-45. 7. Booth C, Silva J, Veys P. Stem cell trans- plantation for the treatment of immu- nodeficiency in children: current status and hopes for the future. Expert review of clinical immunology. 2016;12(7):713- 23. 8. Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, et al. New frontiers in pediatric Allo- SCT. Bone marrow transplantation. 2014;49(9):1139-45. 9. Nieder ML, McDonald GB, Kida A, Hingorani S, Armenian SH, Cooke KR, et al. National Cancer Institute-National Heart, Lung and Blood Institute/pedia- tric Blood and Marrow Transplant Con- sortium First International Consensus Conference on late effects after pedia- tric hematopoietic cell transplantation: long-term organ damage and dysfunc- tion. Biol Blood Marrow Transplant. 2011;17(11):1573-84. 10. Munchel A, Chen A, Symons H. Emer- gent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient. Clinical pediatric emergency medicine. 2011;12(3):233-44. 11. Chow EJ, Anderson L, Baker KS, Bha- tia S, Guilcher GM, Huang JT, et al. Late Effects Surveillance Recommen- dations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children’s Oncology Group Re- port. Biol Blood Marrow Transplant. 2016;22(5):782-95. 12. Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complicati- ons following hematopoietic stem cell transplantation. Hematology/oncology and stem cell therapy. 2010;3(3):143-57. 13. Ahya VN. Noninfectious Acute Lung In- jury Syndromes Early After Hematopoie- tic Stem Cell Transplantation. Clinics in chest medicine. 2017;38(4):595-606. 14. Radhakrishnan SV, Hildebrandt GC. A call to arms: a critical need for interven- tions to limit pulmonary toxicity in the stem cell transplantation patient popu- lation. Current hematologic malignancy reports. 2015;10(1):8-17. 15. Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schultz KR, Wall DA, et al. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consor- tium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015;21(1):67-73. References